Ảnh hưởng của kích hoạt tiếp xúc bề mặt và nhiệt độ lên quá trình đông máu huyết tương với một RNA aptamer hướng tới yếu tố IXa

Durham SJ, Gold JP (2003). Late complications of cardiac surgery. In: Cohn LH (ed) Cardiac surgery in the adult, Chap 19, 3rd edn. McGraw Hill, New York, pp 535–548 Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA (2005) The potential of aptamers as anticoagulants. Trends Cardiovasc Med 15(1):41–45 Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555–583 Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G Jr et al (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22(11):1423–1428 Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902):90–94 Sullenger BA, White RR, Rusconi CP (2003) Therapeutic aptamers and antidotes: a novel approach to safer drug design. Ernst Schering Res Found Workshop 43:217–223 Becker RC (2005) Cell-based models of coagulation: a paradigm in evolution. J Thromb Thrombolysis 20(1):65–68 Howard EL, Becker KC, Rusconi CP, Becker RC (2007) Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 27(4):722–727 Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14(3):408–415 Becker RC (2007) Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol 50(18):1777–1780 Becker RC (2005) Novel constructs for thrombin inhibition. Am Heart J 149(1 Suppl):S61–S72 Becker RC, Oney S, Becker KC, Rusconi CP, Sullenger B (2007) Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie 27(5):378–382 Yavari M, Becker RC (2008) Anticoagulant therapy during cardiopulmonary bypass. J Thromb Thrombolysis 26(3):218–228 Yavari M, Becker RC (2008) Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis 27(1):95–104 Vogler EA, Siedlecki CA (2009) Contact activation of blood-plasma coagulation. Biomaterials 30(10):1857–1869 Vogler EA, Nadeau JG, Graper JC (1997) Contact activation of the plasma coagulation cascade. III. Biophysical aspects of thrombin binding anticoagulants. J Biomed Mat Res 40(1):92–103 Golas A, Parhi P, Dimachkie ZO, Siedlecki CA, Vogler EA (2010) Surface-energy dependent contact activation of blood factor XII. Biomaterials 31(6):1068–1079 Vogler EA, Graper JC, Harper GR, Sugg HW, Lander LM, Brittain WJ (1995) Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res 29(8):1005–1016 Rusconi CP, Yeh A, Lyerly HK, Lawson JH, Sullenger BA (2000) Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 84(5):841–848 Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA et al (2011) Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 32(1):21–31 Povsic TJ, Sullenger BA, Zelenkofske SL, Rusconi CP, Becker RC (2010) Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. J Cardiovasc Transl Res 3(6):704–716 Mitropoulos KA (1999) The levels of factor XIIa generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXII, prekallikrein, high molecular weight kininogen or FXI. Thromb Haemost 82(3):1033–1040 Mitropoulos KA, Martin JC, Stirling Y, Morrisey JH, Cooper JA (1995) Activation of factors XII and VII induced in citrated plasma in the presence of contact surface. Thromb Res 78(1):67–75 Vogler EA, Graper JC, Sugg HW, Lander LM, Brittain WJ (1995) Contact activation of the plasma coagulation cascade. II. Protein adsorption to procoagulant surfaces. J Biomed Mater Res 29(8):1017–1028 Brown B (1973) Hematology principles and procedures. Lea and Febiger, Philadelphia, pp 33–39 Vogler EA, Nadeau JG, Graper JC (1998) Contact activation of the plasma coagulation cascade. III. Biophysical aspects of thrombin-binding anticoagulants. J Biomed Mater Res 40(1):92–103 Zhuo R, Miller R, Bussard KM, Siedlecki CA, Vogler EA (2005) Procoagulant stimulus processing by the intrinsic pathway of blood plasma coagulation. Biomaterials 26(16):2965–2973 Vogler EA, Graper JC, Harper GR, Lander LM, Brittain WJ (1995) Contact activation of the plasma coagulation cascade. I. Procoagulant surface energy and chemistry. J Biomed Mat Res 29:1005–1016 Zhuo R, Miller R, Bussard KM, Siedlecki CA, Vogler EA (2005) Procoagulant stimulus processing by the intrinsic pathway of blood plasma coagulation. Biomaterials 26:2965–2973 Zhuo R, Colombo P, Pantano C, Vogler EA (2005) Silicon oxycarbide glasses for blood-contact applications. Acta Biomater 1:583–589 Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845–867 Vogler EA (2001) On the origins of water wetting terminology. In: Morra M (ed) Water in biomaterials surface science. John Wiley and Sons, New York, pp 150–182 Li Y, Guo L, Zhang F, Zhang Z, Tang J, Xie J (2008) High-sensitive determination of human alpha-thrombin by its 29-mer aptamer in affinity probe capillary electrophoresis. Electrophoresis 29(12):2570–2577